Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF

Ji Eun Jang, June Won Cheong, Soo Jeong Kim, Hyunsoo Cho, Cheolwon Suh, Hyewon Lee, Hyeon Seok Eom, Ho Young Yhim, Won Sik Lee, Chang Ki Min, Jae Hoon Lee, Joon Seong Park, Jin Seok Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To evaluate the feasibility of selecting a mobilization regimen based on the response to induction therapy, we retrospectively analyzed 179 multiple myeloma patients who underwent stem cell mobilization. In comparison with patients who achieved at least a very good partial response (VGPR) to induction therapy and received granulocyte-colony stimulating factor (G-CSF) alone and patients who did not achieve a VGPR and received cyclophosphamide (CY) + G-CSF, treatment-related toxicity was greater and neutrophil engraftment was slower in the CY than the G-CSF group. The rate of requisite mobilization (≥ 2.0 × 106/kg) was similar in both groups. Overall and progression-free survival was not different between patients in the G-CSF group and patients who achieved at least VGPR and received CY + G-CSF. In conclusion, response-adapted selection of a mobilization regimen is appropriate. G-CSF alone should be the preferred treatment for patients who achieved at least a VGPR to induction therapy.

Original languageEnglish
Pages (from-to)1389-1397
Number of pages9
JournalLeukemia and Lymphoma
Volume57
Issue number6
DOIs
Publication statusPublished - 2016 Jun 2

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF'. Together they form a unique fingerprint.

  • Cite this